What PredxBio does

PredxBio is a Pittsburgh-based computational pathology company that develops AI-driven spatial biology software for biopharmaceutical drug development. The company's core product, the SpaceIQ decision-intelligence platform, applies explainable AI to whole-slide tissue images and multi-omic data (H&E, IHC, mIF, IMC, spatial proteomics, and spatial transcriptomics) to characterize tissue organization, cellular microenvironments, and cell–cell interactions across multiple biological scales. The platform is organized into three application layers — Discovery & Mechanism Intelligence, Translational & Clinical Readiness, and Trial & Program-Scale Decision Support — and is positioned to support target and biomarker strategy, patient stratification, trial optimization, and go/no-go decisions in oncology drug programs. The company also retains the legacy HistoMapr-Breast™ computational pathology product for breast cancer diagnosis and prognosis.

PredxBio operates an enterprise-direct, sales-led go-to-market motion targeting two horizontal segments: biopharmaceutical companies (primary) and academic research institutions (secondary). The commercial model begins with collaborative, fee-based research engagements, then transitions customers to subscription/recurring SpaceIQ platform licensing — available as cloud-based access or on-premise deployment — once programs mature. Deployment is supported by a partnership ecosystem spanning imaging (Hamamatsu Photonics), virtual staining (PictorLabs), multi-omic CRO services (Sirona Dx, iCura Diagnostics), and digital pathology platforms (Inspirata, CellNetix). The company markets through scientific conferences (AACR, SITC), content marketing, LinkedIn, YouTube, and its own Spatial Intelligence Summit.

The company is privately held, incorporated in Delaware, with 11–50 employees and headquarters in Pittsburgh, PA. It was founded in 2015 (originally as SpIntellx, rebranded in April 2023) and has raised approximately $1.1M in disclosed equity funding across a 2020 round and a 2023 SEC Form D exempt offering of up to $4M. In December 2025, co-founder S. Chakra Chennubhotla, PhD was appointed CEO, succeeding B. Dusty Majumdar, PhD.

Name

PredxBio

Legal name

PredxBio, Inc.

Website

https://predxbio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

PredxBio builds the SpaceIQ AI-driven spatial biology platform, which applies explainable AI to tissue and multi-omic data to deliver decision-grade biomarkers, patient stratification, and trial optimization for biopharmaceutical drug development and academic oncology research.

Ownership category

akta.pro rank

Product category

Computational Pathology Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Single-Cell & Spatial Omics Services (HLAGANAC), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Spatial biology analytics
• Computational pathology software
• Explainable AI platform
• Tissue intelligence solutions
• Biomarker discovery tools

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software Platform Licensing: PredxBio transitions from collaborative research engagements to secure, scalable, and modular software access. As insights mature from exploration to program dependency, SpaceIQ transitions from collaboration to platform licensing. Deployment models include cloud-based access, on-premise deployment, and enterprise integration.
2. Collaborative Research Engagements: Partners with biopharma teams through collaborative, knowledge-driven research engagements. Revenue generated through research collaboration fees before transitioning to ongoing platform licensing.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

PredxBio develops and licenses the SpaceIQ™ decision-intelligence platform, an AI-driven spatial biology software that combines unbiased spatial analytics with explainable AI to analyze whole slide image and multi-omic tissue data for drug discovery, biomarker development, and clinical trial optimization. The company also offers the HistoMapr-Breast™ computational pathology application for breast cancer diagnosis and provides collaborative research engagements that transition into platform licensing.

Product overview

PredxBio offers the SpaceIQ™ decision intelligence platform as its core product, complemented by specialized sub-products including Discovery & Mechanism Intelligence, Translational & Clinical Readiness, Trial & Program-Scale Decision Support, and the Multi-Omic Co-Analysis feature. The platform is augmented by HistoMapr-Breast™ for computational pathology. Services include collaborative research engagements transitioning to platform licensing. SpaceIQ integrates unbiased spatial analytics with explainable AI to transform complex tissue and multi-omic spatial data into explainable, decision-ready insights across drug discovery and clinical development.

Differentiator

Problem solved

Functional benefit

Brands

• SpaceIQ™: Decision-intelligence platform that transforms spatial and multi-omic tissue data into explainable, decision-ready insights across drug discovery and clinical development.
• HistoMapr-Breast™

Products and services

• SpaceIQ™ Platform An end-to-end decision-intelligence software platform that transforms spatial and multi-omic tissue data into explainable, decision-ready insights across drug discovery and clinical development. Delivered via cloud-based access or on-premise deployment to biopharmaceutical companies and research institutions.
• HistoMapr-Breast™ Computational pathology software that uses explainable AI (xAI) and spatial analytics to help healthcare providers diagnose, prognosticate, and treat breast cancer more efficiently and accurately.
• Collaborative Research Engagements Knowledge-driven research service engagements with biopharma teams, providing a pathway from exploratory research collaboration to SpaceIQ platform licensing as insights mature into program dependencies.
• SaaS for Precision Pathology Software-as-a-service offering that delivers PredxBio's unbiased spatial analytics and explainable AI for accelerated drug discovery, biomarker identification, clinical trials optimization, and precision patient stratification.

Quantifiable outcome

• Earlier go/no-go decisions in drug development
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• Hamamatsu PhotonicscoreStrategic or Co-development Partner · 28 April 2025Strategic collaboration uniting Hamamatsu's advanced MoxiePlex™ multiplex immunofluorescence imaging system with PredxBio's SpaceIQ™ spatial analytics platform to deliver an integrated workflow tailored to immuno-oncology research.
• University of Queensland (Dr. Arutha Kulasinghe, Queensland Spatial Biology Centre)coreStrategic or Co-development Partner · 23 April 2025Collaboration to unlock actionable biology from immunotherapy studies and develop a highly selective, spatial-biomarker-based companion diagnostic for predicting immunotherapy response. Also introduced predictive test framework for translating high-plex spatial data into robust, clinically deployable predictive biomarkers.
• PictorLabsmajorTechnology or Integration · 9 April 2024Strategic partnership to revolutionize cancer research, diagnosis, and treatment by combining PredxBio's spatial analytics with PictorLabs' AI-powered virtual staining technology.
• Sirona DxmajorStrategic or Co-development Partner · 2 April 2024Strategic partnership leveraging Explainable AI-Driven Spatial Biology with SpaceIQ™ to unlock the potential of genomic, proteomic, and transcriptomic data through advanced spatial analytics for drug discovery and development.
• iCura DiagnosticsminorChannel Partner/ Reseller/ Distributor · 18 August 2022Partnership to expand access to advanced spatial analytics and explainable AI products for pathology and oncology research, leveraging iCura's contract research organization capabilities.
• CellNetix Pathology & LaboratoriesminorImplementation/ SI/ Consulting Partner · 20 July 2020Collaboration to validate HistoMapr-Breast™ Platform featuring advanced spatial analytics to provide intelligent guides for pathology laboratories diagnosing and treating breast cancer.

Scale indicators1 record

Recent moves7 records

Expansion highlights6 records

Direct peers

• 10x Genomics: 10x Genomics offers the Xenium spatial transcriptomics platform and配套 Visium HD workflow, competing directly with PredxBio's SpaceIQ in spatial multi-omic analysis for biopharma and academic research customers. Both target tissue-level insights for drug discovery and translational research.
• Akoya Biosciences: Akoya Biosciences provides the PhenoCycler (CODEX) spatial proteomics platform plus Phenoptics analysis software for immuno-oncology biomarker discovery. Direct overlap with PredxBio on spatial proteomics-driven tissue analysis for pharma translational programs.
• NanoString Technologies (Bruker Spatial Biology): NanoString, now part of Bruker Spatial Biology, offers the CosMx SMI spatial molecular imager and GeoMx digital spatial profiler, directly competing with SpaceIQ in high-plex spatial transcriptomics and proteomics for pharma and translational research customers.
• Lunaphore: Lunaphore develops the COMET multiplex staining and staining-and-imaging platform for spatial proteomics with comparable end-user applications in immuno-oncology biomarker discovery, overlapping with PredxBio's spatial biology value proposition.
• PathAI: PathAI applies AI to pathology images for biomarker discovery, diagnostic development, and pharma partnerships, directly overlapping with PredxBio's computational pathology and pharma-services positioning across translational and clinical applications.
• Owkin: Owkin is an AI-biopharma company building pathology AI models and federated learning infrastructure for drug discovery and companion diagnostics, comparable to PredxBio in target customer (pharma), use cases (biomarker/patient stratification), and AI-first computational pathology focus.
• Aignostics: Aignostics builds AI-powered computational pathology models derived from H&E and IHC for biopharma biomarker discovery and CDx development, competing with PredxBio's spatial pathology analytics for similar pharma translational workflows.
• Visiopharm: Visiopharm provides image analysis software for digital pathology with deep tissue phenotyping capabilities used by biopharma and academic labs, overlapping with PredxBio's computational pathology software approach for oncology and translational research.
• Indica Labs: Indica Labs offers HALO and HALO AI digital pathology software for tissue image analysis, including multiplex phenotyping and spatial biology workflows comparable to SpaceIQ's tissue analysis capabilities for pharma and academic users.

Broad incumbents

• Roche (Digital Pathology / navify): Roche's Digital Pathology business (including navify Digital Pathology and the Ventana companion diagnostic franchise) is a broad incumbent serving pharma CDx and pathology AI use cases that partially overlap with PredxBio's biomarker and tissue intelligence offerings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PredxBio